Related Experiment Video
Updated: Jul 21, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
Side Chain-Modified Benzothiazinone Derivatives with Anti-Mycobacterial Activity
Dongguang Fan1, Bin Wang2, Giovanni Stelitano3
1College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Abstract:
Tuberculosis (TB) is a leading infectious disease with serious antibiotic resistance. The benzothiazinone (BTZ) scaffold PBTZ169 kills Mycobacterium tuberculosis (Mtb) through the inhibition of the essential cell wall enzyme decaprenylphosphoryl-β-D-ribose 2'-oxidase (DprE1). PBTZ169 shows anti-TB potential in animal models and pilot clinical tests. Although highly potent, the BTZ type DprE1 inhibitors in general show extremely low aqueous solubility, which adversely affects the drug-like properties. To improve the compounds physicochemical properties, we generated a series of BTZ analogues. Several optimized compounds had MIC values against Mtb lower than 0.01 µM. The representative compound 37 displays improved solubility and bioavailability compared to the lead compound. Additionally, compound 37 shows Mtb-killing ability in an acute infection mouse model.
More Related Videos
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
09:57Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
Published on: December 14, 2016
Related Concept Videos
Antihypertensive Drugs: Thiazide-Class Diuretics
Radical Chain-Growth Polymerization: Overview
Drugs that Destabilize Microtubules
Directing and Steric Effects in Disubstituted Benzene Derivatives
Nomenclature of Aromatic Compounds with a Single Substituent
Diazonium Group Substitution with Halogens and Cyanide: Sandmeyer and Schiemann Reactions